I4909
Ifosfamide
≥98%
Synonyme(s) :
Ifex, N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C7H15Cl2N2O2P
Numéro CAS:
Poids moléculaire :
261.09
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
223-237-3
MDL number:
Assay:
≥98%
Quality level:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderQuality Level
assay
≥98%
shipped in
wet ice
storage temp.
2-8°C
SMILES string
ClCCNP1(=O)OCCCN1CCCl
InChI
1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
InChI key
HOMGKSMUEGBAAB-UHFFFAOYSA-N
Application
- Ewing sarcoma of the pancreas: a pediatric case report and narrative literature review: This study explores the effectiveness of Ifosfamide in the treatment of rare pediatric Ewing sarcoma of the pancreas, providing valuable insights into the chemotherapeutic management of rare cancers (Liu et al., 2024).
- Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience: Highlights the role of Ifosfamide in osteosarcoma treatment as part of a clinical trial, evaluating its impact on survival rates and treatment outcomes (Bastard et al., 2024).
- Case report: Characteristics and nature of primary cardiac synovial sarcoma: Discusses the utilization of Ifosfamide in managing primary cardiac synovial sarcoma, with an emphasis on its pharmacodynamics and therapeutic efficacy (Kawasaki et al., 2024).
- Dedifferentiated liposarcoma of the spermatic cord: Examines Ifosfamide′s mechanism of action in treating dedifferentiated liposarcoma, contributing to the broader understanding of its application in sarcoma therapy (Panther et al., 2024).
- A Rare Case of Extranodal Natural Killer/T-cell Lymphoma, Nasal Type Associated With Hemophagocytic Lymphohistiocytosis in a Patient With Recurrent Sinusitis: This article details the clinical use of Ifosfamide in treating aggressive lymphoma, underscoring its role in complex cases where standard treatments may not suffice (Christensen et al., 2024).
Biochem/physiol Actions
Ifosfamide is a nitrogen mustard compound that is a structural isomer of cyclophosphamide. Ifosfamide is a prodrug that must be transformed by cytochrome P450 to the biologically active component. It is used as an antineoplastic agent in cancer chemotherapy, but ifosfamide is more likely to cause renal toxicity than cyclophosphamide.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B
Classe de stockage
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Contenu apparenté
Cecile Faure-Conter et al.
Pediatric blood & cancer, 61(2), 253-259 (2013-08-14)
Some children with extracranial germ cell tumors (GCT) relapse after or do not respond to first-line treatment combining chemotherapy and surgery, of whom very few experience long-term survival despite multimodal salvage treatment. This prospective study, part of the French TGM95
Evaristus C Mbanefo et al.
Scientific reports, 9(1), 1586-1586 (2019-02-09)
Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites. We previously showed that a single dose of IPSE (Interleukin-4-inducing principle from Schistosoma eggs), a schistosome-derived host modulatory protein, can ameliorate ifosfamide-related cystitis;
S Stacchiotti et al.
European journal of cancer (Oxford, England : 1990), 49(10), 2376-2383 (2013-04-10)
To report on anthracycline-based chemotherapy in a retrospective case-series analysis of solitary fibrous tumour (SFT) patients treated within the Italian Rare Cancer Network. We reviewed a set of SFT treated with chemotherapy since 2002, focusing on anthracycline, administered alone or